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Summary
Background Western Cambodia is the epicentre of Plasmodium falciparum multidrug resistance and is facing high 
rates of dihydroartemisinin–piperaquine treatment failures. Genetic tools to detect the multidrug-resistant parasites 
are needed. Artemisinin resistance can be tracked using the K13 molecular marker, but no marker exists for 
piperaquine resistance. We aimed to identify genetic markers of piperaquine resistance and study their association 
with dihydroartemisinin–piperaquine treatment failures.
Methods We obtained blood samples from Cambodian patients infected with P falciparum and treated with 
dihydroartemisinin–piperaquine. Patients were followed up for 42 days during the years 2009–15. We established in-
vitro and ex-vivo susceptibility proﬁ les for a subset using piperaquine survival assays. We determined whole-genome 
sequences by Illumina paired-reads sequencing, copy number variations by qPCR, RNA concentrations by qRT-PCR, 
and protein concentrations by immunoblotting. Fisher’s exact and non-parametric Wilcoxon rank-sum tests were 
used to identify signiﬁ cant diﬀ erences in single-nucleotide polymorphisms or copy number variants, respectively, for 
diﬀ erential distribution between piperaquine-resistant and piperaquine-sensitive parasite lines.
Findings Whole-genome exon sequence analysis of 31 culture-adapted parasite lines associated ampliﬁ cation of the 
plasmepsin 2–plasmepsin 3 gene cluster with in-vitro piperaquine resistance. Ex-vivo piperaquine survival assay proﬁ les 
of 134 isolates correlated with plasmepsin 2 gene copy number. In 725 patients treated with dihydroartemisinin–
piperaquine, multicopy plasmepsin 2 in the sample collected before treatment was associated with an adjusted hazard 
ratio (aHR) for treatment failure of 20·4 (95% CI 9·1–45·5, p<0·0001). Multicopy plasmepsin 2 predicted 
dihydroartemisinin–piperaquine failures with 0·94 (95% CI 0·88–0·98) sensitivity and 0·77 (0·74–0·81) speciﬁ city. 
Analysis of samples collected across the country from 2002 to 2015 showed that the geographical and temporal 
increase of the proportion of multicopy plasmepsin 2 parasites was highly correlated with increasing dihydro-
artemisinin–piperaquine treatment failure rates (r=0·89 [95% CI 0·77–0·95], p<0·0001, Spearman’s coeﬃ  cient of 
rank correlation). Dihydroartemisinin–piperaquine eﬃ  cacy at day 42 fell below 90% when the proportion of multicopy 
plasmepsin 2 parasites exceeded 22%.
Interpretation Piperaquine resistance in Cambodia is strongly associated with ampliﬁ cation of plasmepsin 2–3, 
encoding haemoglobin-digesting proteases, regardless of the location. Multicopy plasmepsin 2 constitutes a surrogate 
molecular marker to track piperaquine resistance. A molecular toolkit combining plasmepsin 2 with K13 and mdr1 
monitoring should provide timely information for antimalarial treatment and containment policies.
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Introduction
Antimalarial eﬃ  cacy of artemisinin-based combination 
therapies, the ﬁ rst-line treatment for uncomplicated 
Plasmodium falciparum malaria, relies on both 
fast-acting artemisinin derivatives and long-lasting 
partner drugs. Resistance to artemisinin, which is now 
ﬁ xed in western Cambodia and observed across 
southeast Asia, increases the proportion of parasites 
surviving a 3 day course of an artemisinin-based 
combination therapy. Resistance to the partner drug is a 
greater risk when more parasites survive artemisinin 
treatment. The reduced eﬃ  cacy of artemisinin 
derivatives and partner drugs translates into late 
treatment failures and prolonged parasite carriage, 
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thereby increasing the transmission potential of drug-
resistant infections.
In Cambodia, artesunate–meﬂ oquine was chosen as 
the ﬁ rst-line drug in 2001. By 2008, the high frequency of 
treatment failures in western provinces, the epicentre of 
P falciparum multidrug resistance, led to its replacement 
with dihydroartemisinin–piperaquine in those areas 
in 2008, and later throughout Cambodia in 2010. In 
recent years the spread of artemisinin-resistant 
P falciparum, from western Cambodia to neighbouring 
provinces,1–5 has been followed by a substantial increase 
in dihydro artemisinin–piperaquine failure rates. Failures 
are estimated to reach 60%,6–10 indicating a dramatic 
expansion of piperaquine resistance. Until now, the 
detection of piperaquine resistance has been based on 
logistically demanding 42-day follow-up studies of 
patients treated with dihydroartemisinin–piperaquine.11 
The in-vitro piperaquine survival assay (PSA)7 has been 
shown with in-vitro culture-adapted parasites and freshly 
collected ex-vivo patient isolates to detect piperaquine 
resistance and treatment failure more reliably than 
classic dose–response assays.7 The in-vitro PSA therefore 
provides a reliable tool to identify molecular signatures 
associated with resistance.
Here, we used the phenotypic information from the 
PSA to identify genetic marker(s) of piperaquine 
resistance and study their association with dihydro-
artemisinin–piperaquine treatment failures.
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Research in context
Evidence before this study
We searched PubMed for studies on piperaquine resistance 
using the term “resistance” in combination with “falciparum” 
and “piperaquine” on May 19, 2016, without any date or 
language restrictions, and identiﬁ ed 74 publications. 
These publications included clinical trials done in 11 countries 
evaluating the eﬃ  cacy of dihydroartemisinin–piperaquine for 
the treatment of uncomplicated Plasmodium falciparum malaria 
(26 reports) or asymptomatic infections (one report) and for 
intermittent preventive treatment of pregnant women 
(three reports) or infants (ﬁ ve reports). In all studies, cure rates 
were above 90%, except studies done in Cambodia after the 
year 2010, for which cure rates ranging from 85% to 40% were 
recorded. Overall, 26 publications reported susceptibility of 
parasites collected in 15 countries, studied using in-vitro or 
ex-vivo assays. Virtually all isolates tested by standard 
dose–response susceptibility assays (with parasite quantiﬁ cation 
based on isotopes, Sybr Green, or HRP2) were susceptible to 
piperaquine (<100 nmol/L), except those collected in Cambodia 
after 2010 and samples collected in China before 1998 (when 
piperaquine monotherapy was intensively used). Piperaquine 
resistance at present appears conﬁ ned to Cambodia. Resistance 
is a major concern because alternative therapeutic options are 
scarce and the reduced cure rates translate into prolonged 
parasite carriage and increased transmission potential of 
resistant parasites. To map the geographical extension of 
piperaquine resistance and deploy containment measures to 
prevent its further spread, rapid detection tests are needed but 
are lacking at present. Potential molecular signatures associated 
with piperaquine resistance were investigated in 11 studies. The 
only consistently recorded ﬁ nding was an increased proportion 
of single copy mdr1 parasites in piperaquine-resistant areas. This 
marker is not informative for piperaquine resistance because 
wild-type susceptible parasites can also have a single-copy 
mdr1 locus.
Added value of this study
We identiﬁ ed ampliﬁ cation of the plasmepsin 2–3 gene cluster 
encoding proteases involved in haemoglobin degradation as 
the most signiﬁ cant molecular signature associated with 
in-vitro resistance to piperaquine assessed using the 
piperaquine survival assay. Using a large longitudinal 
collection of samples collected during clinical eﬃ  cacy studies 
of dihydroartemisinin–piperaquine done across Cambodia 
since 2009, we examined 725 P falciparum isolates and found 
that an increased plasmepsin 2 gene copy number was 
strongly associated with dihydroartemisinin–piperaquine 
treatment failures. Patients harbouring multicopy plasmepsin 
2 parasites had a 20 times higher risk of recrudescence during 
the 42-day post-treatment follow-up (94% sensitivity and 
77% speciﬁ city). Our retrospective analysis of samples 
collected in Cambodia during the last decade before and after 
introduction of dihydroartemisinin–piperaquine as ﬁ rst-line 
treatment showed that the proportion of multicopy 
plasmepsin 2 parasites correlated with the increase of 
dihydroartemisinin–piperaquine treatment failure rates, from 
2009 to 2015 in western Cambodia and during 2014–15 in 
eastern Cambodia. In areas of artemisinin resistance, the 
clinical eﬃ  cacy of dihydroartemisinin–piperaquine at day 42 
fell under 90% when the local proportion of multicopy 
plasmepsin 2 parasites rose above 22%.
Implications of all the available evidence
Dihydroartemisinin–piperaquine failure rates have increased in 
western Cambodia since 2010 and in eastern Cambodia 
since 2014. They are caused by parasites that are resistant to 
both artemisinin and piperaquine. Combined analysis of 
K13 polymorphisms and plasmepsin 2 copy number represents 
the ﬁ rst informative molecular signature for 
dihydroartemisinin–piperaquine failures. These molecular 
markers can now be used to track emergence and dissemination 
of resistance to artemisinin and piperaquine in ﬁ eld 
populations, especially in areas where piperaquine is being or 
will be recommended in combination with artemisinin 
derivatives as ﬁ rst-line treatment or in preventive treatment for 
infants or pregnant women, as developed in African settings. 
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Methods
Overview
First, the exomes of culture-adapted artemisinin-
resistant Cambodian P falciparum lines deﬁ ned as 
piperaquine-susceptible or piperaquine-resistant based 
on their PSA survival rates7 were compared for single-
nucleotide poly morphisms (SNPs) and copy number 
variations (CNVs). This process identiﬁ ed an increased 
copy number of the plasmepsin 2–plasmepsin 3 gene 
cluster as a putative genetic signature associated with 
in-vitro piperaquine resistance. Increased plasmepsin 2 
gene copy number was then assessed as a candidate 
resistance marker in isolates with documented ex-vivo 
PSA survival rates and in blood samples collected 
during the years 2009–15 from Cambodian patients 
treated with dihydro artemisinin–piperaquine and 
followed up for 42 days. Finally, we investigated the 
geographical and temporal distribution of multicopy 
plasmepsin 2 parasites in the country from 2002 to 2015 
and its correlation with dihydro artemisinin–piperaquine 
treatment failures.
Study sites and patients
Patients with P falciparum malaria were enrolled in 
clinical studies done at health centres located across 
Cambodia during the years 2009–15 (table 1, ﬁ gure 1). 
After obtaining written informed consent, patients were 
treated with dihydro artemisinin–piper aquine (Duo-
Cotecxin [dihydro artemisinin 40 mg and piper aquine 
320 mg], Zhejiang Holley Nanhu Pharamaceutical 
Co Ltd, Jiaxing City, Zhejiang Province, China) and 
followed up for 42 days, as previously described.7,8,10 The 
endpoint to assess the eﬃ  cacy of dihydroartemisinin–
piperaquine was the proportion of PCR-corrected 
recrudescent P falciparum infections at day 42.11 All 
studies were approved by the Ethical Committee for 
Health Research of the Cambodian Ministry of Health. 
Clinical trials were registered at the Australian New 
Zealand Clinical Trials Registry (numbers ACTRN 
12615000793516, 12612000184875, 12612000183886, 
12612000181808, and 12614000344695).
Procedures
Blood samples were collected into acid-citrate-dextrose 
tubes (Becton-Dickinson, Franklin Lakes, NJ, USA) 
before treatment and sent to Institut Pasteur in 
Cambodia within 24 h. A subset of freshly collected 
samples was used to do the ex-vivo PSA.7 All samples 
were cryopreserved in glycerolyte. Red cell pellets were 
stored at –20°C for molecular studies. Blood spots were 
prepared on day 0 and when applicable on the day of 
recrudescence.
Cryopreserved parasites were culture-adapted as 
described.12 Susceptibility to piperaquine was investi-
gated using in-vitro PSA for culture-adapted parasites 
and ex-vivo PSA for fresh isolates. Survival rates were 
assessed microscopically and parasites with a survival 
rate of at least 10% were considered piperaquine-
resistant.7 msp1, msp2, and glurp poly morphisms were 
determined to distinguish re crudescent from new 
infections.13 Sequencing of the K13-propeller domain 
was used to screen for artemisinin resistance.1 
Whole-genome sequencing was done with Illumina 
paired-reads sequencing.1 Data were integrated into the 
Whole-genome Data Manager database14 and exomes of 
piper aquine-resistant and piperaquine-sensitive lines 
were compared after excluding low-coverage positions 
(ie, lower than 25% of the genome-wide mean coverage). 
Genes from highly variable multigene families (var, 
riﬁ n, phist, and stevor) were excluded.1 SNPs and CNVs 
were investigated using PlasmoCNVScan and the 
Phen2gen software (appendix).14 Plasmepsin 2 and mdr1 
Number of 
patients treated 
and followed up 
(n=725)
Number of patients 
classiﬁ ed as 
recrudescent 
(PCR-corrected; n=119)
Number of isolates 
with in-vitro PSA 
survival data
(n=31)
Number of isolates 
with ex-vivo PSA 
survival data
(n=134)
2009
Pailin 32 3 (9·4%) 0 0
Preah Vihear 30 0 0 0
2010
Pailin 21 4 (19·0%) 0 0
Pursat 32 3 (9·4%) 0 0
Rattanakiri 30 0 0 0
2011
Kratié 51 2 (3·9%) 0 0
Preah Vihear 34 2 (5·9%) 0 0
Pursat 41 7 (17·1%) 0 0
2012
Battambang 39 12 (30·8%) 19 0
Kampong Speu 22 0 4 0
Kampong Thom 38 0 2 0
Pursat 23 2 (8·7%) 6 0
2013
Kampot 17 1 (5·9%) 0 0
Kratié 22 0 0 0
Preah Vihear 16 1 (6·3%) 0 0
Rattanakiri 31 1 (3·2%) 0 0
2014
Mondulkiri 39 4 (10·3%) 0 0
Siemreap 40 25 (62·5%) 0 0
Stungtreng 33 11 (33·3%) 0 0
Rattanakiri 34 5 (14·7%) 0 34
2015
Mondulkiri 16 4 (25·0%) 0 16
Rattanakiri 54 16 (29·6%) 0 54
Siemreap 17 10 (58·8%) 0 17
Stungtreng 13 6 (46·1%) 0 13
Site location and years of collection are provided for isolates with in-vitro and ex-vivo piperaquine survival assay (PSA) 
proﬁ les (see ﬁ gure 1 for a map of the study site locations). Data are n or n (%).
Table 1: Proportion of PCR-corrected Plasmodium falciparum recrudescence recorded at day 42 in 2009–15 in 
12 provinces across Cambodia in patients treated with a 3-day course of dihydroartemisinin–piperaquine
See Online for appendix
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copy number was determined by qPCR (appendix). 
Steady-state plasmepsin 2 mRNA concentrations were 
measured by RT-qPCR (appendix) and plasmepsin 2 
protein expression by immunoblotting (appendix).
Statistical analysis
Data were analysed with MedCalc version 12 (Mariakerke, 
Belgium). Kruskal-Wallis or Mann-Whitney tests were 
used for non-parametric comparisons and Student’s t test 
or one-way ANOVA were used for parametric comparisons. 
For proportions (expressed with per centages and 95% CIs), 
we used χ² or Fisher’s exact tests. Manhattan plots were 
generated using the SNPEVG software.15 We did an SNP-
wise analysis using a homemade script developed by FA 
and BS and used Fisher’s exact test to identify signiﬁ cant 
SNP diﬀ erences between piperaquine-resistant and 
piperaquine-sensitive parasite lines. We tested CNVs for 
diﬀ erential distribution between piperaquine-resistant and 
piperaquine-sensitive parasite lines using a non-parametric 
Wilcoxon rank-sum test. The Bonferroni and the 
Benjamini-Hochberg corrections were used to assess 
genome-wide signiﬁ cance and adjust p values when 
statistical tests were done simultaneously on a single 
dataset (appendix). Relative risks were estimated using the 
Mantel-Haenszel test. Associations between a cumulative 
risk of failure at day 42 and molecular signatures associated 
with piperaquine resistance were assessed by survival 
analysis. Curves were compared with the Mantel-Haenszel 
log-rank test. The Cox proportional-hazards regression 
model was used to assess the association between parasite 
genotypes (K13 mutations, plasmepsin 2, and mdr1 copy 
number), sampling locations, and treatment responses. A 
linear regression analysis was used to assess the association 
between the eﬃ  cacy of dihydro artemisinin–piperaquine 
and the proportion of parasites with multicopy plasmepsin 2. 
We deemed p values of less than 0·05 as signiﬁ cant.
Role of the funding source
The funders of this study had no role in study design, 
data collection, data analysis, data interpretation, writing 
of the report, and the decision to submit. The 
corresponding author had full access to all data in the 
study and ﬁ nal responsibility for the decision to submit 
for publication.
Results
From Sept 15, 2009, to Feb 23, 2015, 725 patients were 
enrolled in clinical studies to assess the eﬃ  cacy of the 
standard 3-day dihydro artemisinin–piperaquine treat-
ment. By 2015, the cumulative proportion of P falciparum 
recrudescence at day 42 after PCR correction was 
16·4% (119 of 725 patients), ranging from 0% to 62·5% 
depending on the site and the year of study (table 1, 
ﬁ gure 1).
Whole-genome sequences were obtained from 
31 artemisinin-resistant (K13 C580Y mutant) 
culture-adapted parasite lines collected in Cambodia 
Thailand
Laos
Vietnam
Phnom Penh
Pailin Battambang
Siem Reap
Preah Vihear
Pursat
Kampong Speu
Stungtreng
Rattanakiri
Mondulkiri
Kampot
Kampong Thom
Kratié
Figure 1: Location of study sites (provinces) where dihydroartemisinin–piperaquine clinical eﬃ  cacy studies 
were done in 2009–15 (42-day follow-up)
Year Site location In-vitro PSA 
survival rate (%)
In-vitro susceptibility 
to PPQ*
DNA expansion 
type†
3D7 ·· ·· 0·1% Sensitive No ampliﬁ cation
6273 2012 Kampong Speu 0·2% Sensitive No ampliﬁ cation
6337 2012 Kampong Speu 0·4% Sensitive No ampliﬁ cation
6403 2012 Pursat 0·5% Sensitive No ampliﬁ cation
6267 2012 Kampong Speu 0·5% Sensitive No ampliﬁ cation
6349 2012 Kampong Thom 0·6% Sensitive No ampliﬁ cation
6237 2012 Kampong Thom 0·8% Sensitive No ampliﬁ cation
6410 2012 Battambang 6·0% Sensitive No ampliﬁ cation
6369 2012 Pursat 6·4% Sensitive Type 2
6395 2012 Battambang 19·2% Resistant No ampliﬁ cation
6341 2012 Pursat 25·8% Resistant Type 2
6280 2012 Battambang 28·9% Resistant Type 2
6246 2012 Kampong Speu 36·9% Resistant No ampliﬁ cation
6293 2012 Battambang 39·3% Resistant Type 2
6391 2012 Battambang 39·4% Resistant Type 1
6272 2012 Battambang 40·0% Resistant Type 2
6218 2012 Battambang 40·8% Resistant Type 1
6302 2012 Battambang 42·5% Resistant Type 1
6229 2012 Battambang 46·6% Resistant Type 1
6443 2012 Battambang 49·6% Resistant Type 1
6430 2012 Battambang 51·3% Resistant Type 1
6429 2012 Pursat 51·8% Resistant Type 1
6365 2012 Battambang 51·8% Resistant Type 2
6394 2012 Battambang 56·7% Resistant Type 1
6219 2012 Battambang 58·6% Resistant Type 3
6408 2012 Battambang 58·7% Resistant Type 3
(Table 2 continues on next page)
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in 2012, including 23 piperaquine-resistant and eight 
piperaquine-sensitive lines as deﬁ ned by their in-vitro 
PSA survival rates (table 2). We recorded 120 691 exomic 
(coding sequence) SNPs. Genome-wide association 
analyses of SNPs identiﬁ ed signiﬁ cant diﬀ erences 
between resistant and sensitive lines at two positions 
located in adjacent genes on chromosome 4: 
position 896588 of PF3D7_0420000 (encoding a putative 
zinc-ﬁ nger protein; p<3·56 × 10–7, Fisher’s exact test; 
p=0·042 after Bonferroni correction) and position 908385 
of PF3D7_0420100 (encoding a Rio2 Ser–Thr protein 
kinase; p<3·56 × 10–7, Fisher’s exact test; p=0·042 after 
Bonferroni correction). However, these positions (and 
indeed the sequences of both genes) were ambiguous 
with variable proportions of wild-type and mutant 
nucleotides, precluding identiﬁ cation of speciﬁ c 
resistance-associated mutations, and were not studied 
further (appendix).
By contrast, signals of gene ampliﬁ cation were detected 
in the piperaquine-resistant group for two adjacent genes 
from the cluster located on chromosome 14 that encode 
haemoglobin-digesting proteases known as plasmepsins 
(p=0·03795 Wilcoxon test with Benjamini-Hochberg 
correction; ﬁ gure 2, table 3). Irrespective of piperaquine 
susceptibility, all plasmepsin 3 sequences were wild type 
and all plasmepsin 2 sequences had a Q442H plasmepsin 2 
polymorphism, which has been frequently recorded in 
reference laboratory lines or wild isolates. The correlation 
between in-vitro PSA survival rates and plasmepsin 2–3 
copy number was highly signiﬁ cant (r=0·83 [95% CI 
0·67–0·91], p<0·0001 for plasmepsin 2 copy number and 
r=0·85 [0·71–0·93], p<0·0001 for plasmepsin 3 copy 
number). We recorded three diﬀ erent DNA expansion 
proﬁ les (table 2, appendix). In-vitro PSA survival rates 
were signiﬁ cantly lower in parasites harbouring DNA 
expansion type 2 (n=6, median PSA survival rate 34·1% 
[IQR 25·8–40·0]) compared with those harbouring DNA 
expansion type 1 (n=13, median PSA survival rate 51·8% 
[IQR 45·6–61·7], p=0·006, Mann-Whitney test) or type 3 
(n=3, median PSA survival rate 58·7%, p=0·02, 
Mann-Whitney test).
Conversely, a cluster of ﬁ ve genes on chromosome 5 
(PF3D7_0531700, PF3D7_0522900, PF3D7_0523000, 
PF3D7_0523100, and PF3D7_0523200), which included 
mdr1, had increased copy numbers in sensitive lines. 
mdr1 was ampliﬁ ed in ﬁ ve of eight piperaquine-sensitive 
lines but in none of the 23 piperaquine-resistant lines 
(p=0·015, Wilcoxon test; appendix).
To conﬁ rm the association between plasmepsin CNV 
and ex-vivo PSA survival rate, we used plasmepsin 2 as an 
amplicon reporter. First, we optimised a qPCR method to 
assess plasmepsin 2 gene copy number (appendix). 
Plasmepsin 2 copy number detected by qPCR was 100% 
concordant with the whole-genome sequencing estimates 
for the 31 culture-adapted parasites (p<0·0001, Fisher’s 
test). From a set of 134 isolates with known ex-vivo PSA 
proﬁ les, plasmepsin 2 was ampliﬁ ed in 67 of 
69 piperaquine-resistant parasites (50, 15, and two isolates 
with two, three, or four plasmepsin 2 copies, respectively), 
and zero of 65 piperaquine-susceptible parasites 
(ﬁ gure 3). The median ex-vivo PSA survival rate was 
signiﬁ cantly higher in isolates with at least two 
plasmepsin 2 copies compared with those with 
unampliﬁ ed plasmepsin 2 (51·7% [IQR 29·7–75·1] vs 
0·004% [0·003–0·39]; p<0·0001, Mann-Whitney test). An 
increased plasmepsin 2 copy number predicted ex-vivo 
piperaquine resistance with a sensitivity of 0·97 (95% CI 
For more on the Q442H PfPM2 
polymorphism see http://
plasmodb.org/plasmo
Year Site location In-vitro PSA 
survival rate (%)
In-vitro susceptibility 
to PPQ*
DNA expansion 
type†
(Continued from previous page)
6224 2012 Pursat 61·4% Resistant Type 1
6431 2012 Battambang 61·5% Resistant Type 1
6320 2012 Battambang 62·1% Resistant Type 1
6261 2012 Pursat 70·5% Resistant Type 1
6411 2012 Battambang 71·6% Resistant Type 1
6427 2012 Battambang 77·4% Resistant Type 3
The last column lists the DNA expansion types recorded in the region of chromosome 14 encoding the plasmepsin 1–4 
haemoglobinases. *Threshold used to deﬁ ne in-vitro susceptibility to PPQ: sensitive if survival rates were less than 10% 
and resistant if survival rates were 10% or more. †See appendix for details. 
Table 2: Details of the 31 K13-C580Y mutant, piperaquine (PPQ)-resistant and PPQ-sensitive culture–
adapted parasites analysed by whole-genome sequencing and compared with the 3D7 reference line
4·61
4·15
3·69
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Figure 2: Manhattan plot showing the signiﬁ cance of copy number variations between whole-genome 
exome sequences of 23 piperaquine-resistant and eight piperaquine-sensitive culture-adapted lines 
collected in Cambodia in 2012 and phenotyped using the in-vitro piperaquine survival assay
Each dot represents a gene in the set of 31 culture-adapted parasites, according to chromosome. The x axis 
represents genomic location, and the y axis represents the log10 transformed Wilcoxon test p values. *Wilcoxon test 
p=0·139; after Benjamini-Hochberg correction, only two genes, PF3D7_1408000 (plasmepsin 2) and 
PF3D7_1408100 (plasmepsin 3) achieved genome-wide signiﬁ cance (p=0·03795). 
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0·90–0·99) and speciﬁ city of 1·00 (0·65–1·00). K13 
polymorphisms were detected in 65 piperaquine-resistant 
and 17 piperaquine-susceptible isolates (ﬁ gure 3). Only 
four of 69 piperaquine-resistant isolates harboured a 
wild-type K13 sequence. In a multiple regression analysis, 
increased plasmepsin 2 copy number was more strongly 
associated than K13 mutations with in-vitro piperaquine 
resistance (rpartial=0·94, p<0·0001 and rpartial=0·25, p=0·004, 
respectively).
Plasmepsin 2 transcript concentrations were 4·1–5·3 
times  higher in the piperaquine-resistant line ID_6320 
compared with the piperaquine-sensitive line ID_6267 at 
all timepoints of the intra-erythrocytic cycle investigated. 
Plasmepsin 2 protein concentrations were at least two 
times higher in piperaquine-resistant parasites ID_6408 
compared with the sensitive line ID_6267 (appendix). 
This ﬁ nding is consistent with increased protein 
concentrations in the multicopy plasmepsin 2 lines 
studied. However, further work is required to expand this 
analysis to additional lines.
We then explored the association between plasmepsin 
2 CNV and dihydroartemisinin–piperaquine treatment 
outcome in the isolates from 725 patients collected 
before dihydroartemisinin–piperaquine treat ment, of 
whom 119 experienced recrudescence between day 12 
and day 42 (ﬁ gure 4). Plasmepsin 2 was unampliﬁ ed in 
476 (65·7%) of 725 isolates, had two copies in 
153 (21·1%) of 725 isolates, and three or more copies in 
96 (13·2%) of 725 isolates. Only seven (1·5%) of 
476 patients with unampliﬁ ed plasmepsin 2 parasites 
had recrudesced by day 42 compared with 112 (45·0%) 
of 249 patients infected with multicopy plasmepsin 2 
parasites (relative risk [RR] 22·8 [95% CI 10·7–48·6], 
p<0·0001). Recrudescence was more frequent for 
isolates with three or more plasmepsin 2 copies 
compared with those with two copies (52 [54·2%] of 
96 vs 60 [39·2%] of 153, p=0·02). The cumulative 
incidence of dihydro artemisinin–piper aquine 
treatment failure increased with increasing plasmepsin 
2 gene copies: unampliﬁ ed versus two copies, hazard 
ratio (HR) 32·2 (95% CI 17·9–58·0), p<0·0001; 
unampliﬁ ed versus three copies, HR 49·0 (23·0–104·2), 
p<0·0001; or two copies versus three or more copies, 
HR 1·53 (1·04–2·25), p=0·017 (ﬁ gure 5A). The mean 
time to recrudescence decreased with increasing 
plasmepsin 2 copy number: 41·9 days (95% CI 
41·8–42·0) for patients with unampliﬁ ed plasmepsin 2, 
36·0 days (34·6–37·4) for those with two copies, or 
34·0 days (32·1–35·0) for those with three or more 
copies. Increased plasmepsin 2 copy number predicted 
dihydroartemisinin–piperaquine treatment failures 
with a sensitivity of 0·94 (95% CI 0·88–0·98) and a 
speciﬁ city of 0·77 (0·74–0·81). The AUC (area under 
the ROC curve) was 0·86 (95% CI 0·83–0·88), 
Gene description Chromosome 
number
Unadjusted 
Wilcoxon p 
value
Bonferroni* Benjamini-Hochberg*
PF3D7_1408000 Plasmepsin 2 14 2·43 × 10–5 0·1139 0·03795
PF3D7_1408100 Plasmepsin 3, histo-aspartic protease (HAP) 14 2·43 × 10–5 0·1139 0·03795
PF3D7_0422000 Steroid dehydrogenase, putative 4 6·54 × 10–5 0·306 0·0765
PF3D7_0700800 Pfmc-2TM Maurer’s cleft two transmembrane protein (MC-2TM) 7 4·22 × 10–4 1 0·2468
PF3D7_1353100 Plasmodium exported protein, unknown function 13 4·22 × 10–4 1 0·2468
PF3D7_0713100 Pfmc-2TM Maurer’s cleft two transmembrane protein (MC-2TM) 7 6·65 × 10–4 1 0·3112
PF3D7_0605300 Ser–Thr protein kinase (ARK1) 6 6·65 × 10–4 1 0·3112
PF3D7_0508400 Transcription factor IIb, putative 5 1·02 × 10–3 1 0·4143
PF3D7_0715100 Conserved Plasmodium protein, unknown function 7 1·06 × 10–3 1 0·4143
PF3D7_1211000 Kinesin-like protein, putative 12 1·25 × 10–3 1 0·4208
PF3D7_1304500 Small heat shock protein, putative 13 1·52 × 10–3 1 0·4208
PF3D7_1120100 Phosphoglycerate mutase, putative (PGM1) 11 1·52 × 10–3 1 0·4208
PF3D7_0315600 Conserved Plasmodium protein, unknown function 3 1·52 × 10–3 1 0·4208
PF3D7_0800700 Surface-associated interspersed gene 8,3 (SURFIN8,3) (SURF8,3) 8 1·52 × 10–3 1 0·4208
PF3D7_1117700 GTP-binding nuclear protein ran/tc4 (RAN) 11 1·85 × 10–3 1 0·4572
PF3D7_0909500 Subpellicular microtubule protein 1, putative (SPM1) 9 1·85 × 10–3 1 0·4572
PF3D7_1310200 Conserved Plasmodium protein, unknown function 13 2·24 × 10–3 1 0·4995
PF3D7_0925900 Conserved Plasmodium protein, unknown function 9 2·24 × 10–3 1 0·4995
PF3D7_0322000 Peptidyl-prolyl cis-trans isomerase (CYP19A) 3 2·69 × 10–3 1 0·5254
*Based on 4422 genes included in the analysis (total of 4678 screened genes; 256 genes with <500 bp were excluded from the ﬁ nal analysis).
Table 3: List of genes with copy number variation most strongly associated with in-vitro piperaquine resistance expressed by the piperaquine survival assay
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signiﬁ cantly diﬀ erent from 0·5, the reference value of 
the null hypothesis (p>0·0001). 
Among the 725 patients treated with dihydro-
artemisinin–piperaquine, K13 mutants were detected in 
443 (61·1%) of 725 day 0 isolates (ﬁ gure 5B). Of these, 
116 (26·2%) of 443 were from patients who failed 
dihydroartemisinin–piperaquine treatment by day 42 
compared with three (1·1%) of 282 from patients 
harbouring K13 wild-type parasites (RR 24·6 [95% CI 
7·9–76·7], p<0·0001). A single mdr1 gene copy was 
detected in 610 (84·1%) of 725 day 0 isolates. 
Dihydroartemisinin–piperaquine failures were record ed 
in 112 (18·4%) of 610 patients infected with parasites 
harbouring a single mdr1 copy and seven (6·1%) of 
115 patients infected with multicopy mdr1 parasites 
(RR 3·0 [95% CI 1·4–6·3], p=0·003). The cumulative 
incidence of dihydroartemisinin–piperaquine treatment 
failure did not increase with increasing age (stratiﬁ ed in 
three classes: 0–15 years, 16–30 years, and >30 years; 
p=0·1809, log-rank test) or with increasing parasite 
numbers in isolates collected before dihydroartemisinin–
piperaquine treatment (stratiﬁ ed in four classes: 
<5000 parasites per μL, 5001–20 000 parasites per μL, 
20 001–50 000 parasites per μL, and >50 000 parasites 
per μL; p=0·4612, log-rank test).
After controlling for K13 and mdr1 genotypes in a Cox 
proportional-hazards regression model, plasmepsin 2 
copy number (any increase compared with non-
ampliﬁ cation) was the most signiﬁ cant molecular 
signature associated with dihydroartemisinin–
piperaquine treatment failure (adjusted HR [aHR] 20·4 
[95% CI 9·1–45·5], p<0·0001), followed by K13 mutation 
(aHR 5·5 [1·7–18·3], p=0·005), then mdr1 single copy 
(aHR 2·05 [0·95–4·42], p=0·06). The cumulative 
incidence of dihydroartemisinin–piperaquine treatment 
failure among patients harbouring artemisinin-resistant 
para sites (ie, an artemisinin resistance-associated K13 
mutation) increased signi ﬁ cantly with plasmepsin 2 copy 
number (unampliﬁ ed vs two or more copies, seven [3·3%] 
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Figure 3: Ex-vivo piperaquine survival assay (PSA) survival rates and single 
(n=67) and multicopy plasmepsin 2 (n=67) as estimated by qPCR in isolates 
collected before dihydroartemisinin–piperaquine (DHA–PPQ) treatment 
stratiﬁ ed by K13 genotype
Patients were enrolled in clinical studies done in 2014–15 in Mondulkiri, 
Rattanakiri, Siem Reap, and Stungtreng provinces (see table 1). 
K13 polymorphisms were detected in 65 of 69 piperaquine-resistant isolates 
(64 C580Y, one Y493H) and 17 of 65 piperaquine-susceptible isolates (15 C580Y, 
one C469F, and one A626E). Three parasite lines with discordant data were 
recorded: two resistant lines with non-ampliﬁ ed plasmepsin 2 and plasmepsin 3 
loci (6246 and 6395) and one sensitive line with two plasmepsin 2 copies 
(6369; table 2). The ex-vivo PSA survival rate (%) corresponds to the ratio of 
number of viable parasites in the PPQ-exposed cultures versus the number of 
viable parasites in the non-exposed culture.
Patients treated with DHA-PPQ (40 mg DHA and 
320 mg PPQ) and followed up until recrudescence 
of parasitaemia or day 42 (n=725)
Plasmodium falciparum fresh isolates collected 
from 134 patients tested for:
•  ex-vivo PSA survival rate
•  qPCR plasmepsin 2
31 C580Y K13-mutant P falciparum isolates 
culture-adapted collected from 23 recrudescent
and eight non-recrudescent patients were 
used for:
•  in-vitro PSA testing
•  whole-genome sequencing
•  plasmepsin 2 copy number estimation by qPCR
Outcomes at day 42
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Figure 4: Patients enrolled in clinical studies done in 2009–15 in 12 provinces across Cambodia to assess the 
eﬃ  cacy of the 3-day dihydroartemisinin–piperaquine (DHA–PPQ) regimen, and isolates used to detect 
molecular signatures associated with in-vitro piperaquine survival assay (PSA) resistance and DHA–PPQ 
clinical failure
Supervised DHA–PPQ was given once daily for 3 days (day 0, 24 h, 48 h). Dosing was based on bodyweight: 
less than 19 kg, 40 mg DHA–320 mg PPQ per day; 19–29 kg, 60 mg DHA–480 mg PPQ per day; 30–39 kg, 80 mg 
DHA–640 mg PPQ per day; greater than 40 kg, 20 mg DHA–960 mg PPQ per day. For children unable to swallow 
tablets, DHA–PPQ was dissolved in 5 mL of water. Patients were observed for 1 h post-dosing and were re-dosed 
with a full or half dose if vomiting occurred within 30 min or between 31 and 60 min, respectively. Those who 
vomited after the second dose were withdrawn from the study and were given parenteral rescue treatment 
(intramuscular artemether). Patients with axillary temperatures of 37·5°C were treated with paracetamol. Patients 
were seen daily to day 3 and then weekly for 6 weeks (day 42) for clinical examinations (axillary temperature, 
symptom check) and malaria blood ﬁ lms. Home visits were done if patients failed to come back for their follow-up 
appointments. Withdrawn patients, patients lost to follow-up, and patients classiﬁ ed as reinfected (based on 
msp1, msp2, and glurp genotypes) were excluded from the analysis.
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of 208 vs 109 [46·4%] of 235; HR 17·5 [95% CI 
12·2–25·2]).
CNVs in plasmepsin 2 were investigated in 1252 samples 
collected across Cambodia from 2002 to 2015 (ie, before 
and after the introduction of dihydro arte mi sinin–
piperaquine). This sample included 527 archived isolates 
in addition to the 725 studied above (appendix). A 
longitudinal sampling was done in Pailin (western 
Cambodia) and Rattanakiri (eastern Cambodia), where 
dihydroartemisinin–piperaquine was introduced in 2008 
and 2010, respectively. In Pailin, the proportion of 
multicopy plasmepsin 2 parasites increased from 27·9% 
(19 of 68) in 2008–09 to 91·2% (52 of 57) in 2014–15. In 
Rattanakiri, multicopy plasmepsin 2 parasites were 
infrequent until 2012–13 (3·2% [one of 31]) but increased 
to 45·5% (40 of 88) in 2014–15 (appendix). A steady 
increase of multicopy plasmepsin 2 parasites after 
introduction of dihydroartemisinin–piperaquine was 
recorded in other provinces as well (Preah Vihear, Pursat; 
appendix).
In the 12 sites where dihydroartemisinin–piperaquine 
eﬃ  cacy studies were done in 2009–15, the proportion of 
multicopy plasmepsin 2 isolates was negatively correlated 
with day 42 cure rates (r=0·89 [95% CI 0·77–0·95], 
p<0·0001; appendix). A Cox regression model showed that 
the risk of recrudescence following a dihydroartemisinin–
piper aquine 3-day course was signiﬁ cantly associated 
(p<2 × 10–16) with the presence of multicopy plasmepsin 2 
parasites on day 0 irrespective of the site of enrol-
ment (appendix). A linear regression model showed that 
the clinical eﬃ  cacy of dihydroartemisinin–piperaquine at 
day 42 fell below 90% when the proportion of multicopy 
plasmepsin 2 parasites on K13-mutant genetic background 
rose above 22%.
Discussion
Following reports of increasing failure of artesunate–
meﬂ oquine in western Cambodia, dihydro arte mi-
sinin–piperaquine was adopted in 2008 in the western 
provinces and implemented nationwide in 2010. Resistance 
to this combination has recently accelerated to levels that 
render it widely ineﬀ ective.1 The dearth of alternatives 
creates a perilous situation whereby these multi-
drug-resistant infections might become untreatable and 
spread to other regions with endemic malaria.
The strategy used here to search for genetic associations 
with piperaquine resistance relied on genome-wide 
sequence comparisons of a set of artemisinin-resistant 
parasite lines collected in Cambodia in 2012, all harbouring 
the C580Y artemisinin resistance mutation and presenting 
in-vitro PSA survival rates indicative of piperaquine 
resistance or susceptibility. We reasoned that such a 
focused sampling in a geographically restricted population 
would reduce the genetic noise of artemisinin responses 
and population structure. Results identiﬁ ed ampliﬁ cation 
of the plasmepsin 2–3 cluster as a putative genetic event 
associated with piperaquine resistance. To conﬁ rm this 
association across the country, we focused on plasmepsin 
2, located in the centre of the amplicon. Plasmepsin 2 
ampliﬁ cation strongly correlated with ex-vivo PSA survival 
rates irrespective of artemisinin susceptibility and was 
highly predictive of dihydro artemisinin–piperaquine 
failures in all geographical areas of Cambodia. Plasmepsin 
2 ampliﬁ cation thus represents an informative marker for 
piperaquine resistance.
The strong association between K13 polymorphisms and 
plasmepsin 2 ampliﬁ cation in the Cambodian parasites 
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Figure 5: Cumulative proportion of non-recrudescent patients treated with a 3-day course of 
dihydroartemisinin–piperaquine
(A) Plasmepsin 2 (PM2) gene copy number. Log-rank test: p<0·0001 overall; p<0·0001 (hazard ratio [HR] 32·2 
[95% CI 17·9–58·0]) for single copy vs two copies; p<0·0001 (HR 49·0 [23·0–104·2]) for single copy vs three of 
more copies; p=0·017 (HR 1·53 [1·04–2·25]) for two copies vs three or more copies. (B) PM2 gene copy number 
and K13 genotype detected in isolates collected at the time of enrolment, before treatment. Log-rank test: 
p<0·0001 overall; p<0·0001 for K13 wild-type–PM2 single copy vs K13 wild-type–PM2 multicopy; p=0·002 for K13 
wild-type–PM2 single copy vs K13 mutant–PM2 single copy; p<0·0001 for K13 wild-type–PM2 single copy vs K13 
mutant–PM2 multicopy; p=0·001 (HR 6·9 [0·5–96·6]) for K13 wild-type–PM2 multicopy vs K13 mutant–PM2 single 
copy; p=0·07 (HR 2·6 [1·3–5·5]) for K13 wild-type–PM2 multicopy vs K13 mutant–PM2 multicopy; p<0·0001 
(HR 17·5 [12·2–25·2]) for K13 mutant–PM2 single copy vs K13 mutant–PM2 multicopy.
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studied herein most likely reﬂ ects the history of drug 
selection in Cambodia. The proportion of isolates with 
diﬀ erent K13–plasmepsin 2 combinations (appendix) is 
con sistent with a stepwise selection ﬁ rst for artemisinin 
resistance then for piperaquine resistance. This scenario is 
in line with the delayed appearance of multicopy 
plasmepsin 2 parasites in eastern provinces where the 
emergence of artemisinin resistance was delayed 
compared with western provinces (appendix). Dihydro-
arte misinin–piperaquine treatment failures were rare in 
eastern Cambodia by 2013, conﬁ rming observations by 
others6 but increased steadily in 2014 to reach a high 
frequency by 2015. Most treatment failures had a single 
gene copy of mdr1 (112 [94·1%] of 119), conﬁ rming earlier 
reports of failures.6–9 The presence of single copy mdr1 is 
consistent with data reported for in-vitro-selected 
piperaquine-resistant Dd2 parasites16 and analysis of ﬁ eld 
samples from Cambodia, suggesting opposing resistance 
mechanisms against these molecules.17 We did not observe 
the crt C101F mutation recorded in a piper aquine-pressured 
parasite line selected in vitro. Thus, our data show that 
although the most informative marker for piperaquine 
resistance is plasmepsin 2 copy number, mutation of K13 
alongside a single mdr1 gene copy contributes to the di-
hydro artemisinin–piperaquine failure phenotype. This 
ﬁ nding does not exclude the possibility that additional 
genes contribute to piperaquine resistance. In particular, 
the signiﬁ cance of the mutations observed for 
PF3D7_0420000 and PF3D7_0420100 is unclear. Whether 
the notable sequence heterogeneity of both genes reﬂ ected 
ongoing purifying selection associated with piperaquine 
resistance or loss of meﬂ oquine resistance is uncertain. 
Analysis of a larger number of isolates with documented 
phenotypes for both meﬂ oquine and piperaquine is 
needed to address this question.
Drug-selected gene ampliﬁ cation is a well-known 
phenomenon in malaria parasites.18–21 The size of the 
amplicons on chromosome 14 varied depending on the 
isolate, as reported for mdr1.22 Gene ampliﬁ cation, which is 
more frequent than point mutation in P falciparum 
parasites,22 is consistent with the remarkably rapid rise and 
spread of piperaquine resistance in Cambodia. Conversely, 
mdr1 de-ampliﬁ cation, con sistent with regained 
susceptibility to meﬂ oquine, occurred in Cambodia in 
recent years,6,8,23 and, as shown here, is associated with the 
emergence of piperaquine-resistant strains.
Plasmepsins are expressed during the intra-erythrocytic 
asexual blood stage cycle and by sexual stage gametocytes 
that can be transmitted to the mosquito vector. All four 
plasmepsins are located in the digestive vacuole of 
intra-erythrocytic developmental forms where they 
engage in diﬀ erent steps of haemoglobin degradation. 
Studies of parasites disrupted in the plasmepsin genes 
pointed to redundancy in the haemoglobin degradation 
machinery.24 To our knowledge, there are no reported 
studies about the consequences of over expressing these 
proteases. We show here that plasmepsin 2 ampliﬁ cation 
is associated with a notable increase of steady-state 
mRNA and protein concentrations in two culture-adapted 
isolates. This observation needs to be conﬁ rmed with 
additional isolates. A reasonable hypothesis is that the 
ampliﬁ cation of plasmepsins overcomes the inhibitory 
eﬀ ect of piperaquine on haemoglobin degradation and 
haem detoxiﬁ cation, possibly by reducing concentrations 
of reactive haem species that are preferred substrates for 
piperaquine binding. Piperaquine-treated trophozoites 
have been shown to possess large digestive vacuoles 
containing membrane-bound packets of undigested 
haemoglobin.25 The observation that piperaquine-
resistant parasites have a single mdr1 copy is consistent 
with this scenario, since maintenance of a single mdr1 
copy (or reversion to a single copy) might avoid importing 
excessive amounts of piperaquine into the digestive 
vacuole (appendix).26,27
We note that the association of piperaquine resistance 
with ampliﬁ cation of the plasmepsin 2–3 cluster on 
chromosome 14 is not proof of causality. The structured 
populations of P falciparum parasites in Cambodia28 
might confound the robustness of the association and 
additional loci might also contribute to piperaquine 
resistance. The present ﬁ ndings should be complemented 
with laboratory investigations of the cellular con-
sequences of this ampliﬁ cation on the parasite response 
to piperaquine and on parasite ﬁ tness and transmissibility. 
Nonetheless, our data are timely in providing a molecular 
tool that predicts the appearance of piperaquine 
resistance in endemic settings.
Piperaquine is a well-tolerated partner drug used in 
combination with artemisinin derivatives or the ozonide 
compound arterolane (OZ277).29 The mechanism of 
piperaquine resistance in the speciﬁ c context of 
Cambodia, where artemisinin resistance is nearly ﬁ xed 
and drug pressure is high, might not extrapolate to areas 
where artemisinin resistance has not yet been 
documented. Nevertheless, we propose to extend the 
assessment of plasmepsin 2 gene copy number to areas 
where piperaquine is being used in artemisinin-based 
com bination therapies at a very large scale, and to 
combine this assay with K13 sequencing to localise areas 
of parasite resistance to both components. In Cambodia, 
where the rapid failure of ﬁ rst-line artemisinin-based 
combination therapies is jeopardising elimination eﬀ orts 
and accelerating the emergence and spread of resistance, 
the opposing susceptibility between meﬂ oquine and 
piperaquine could be used to implement new strategies 
based on artemisinin-based combination drug rotation, 
sequential administration, or triple combinations 
including both artemisinin-based combination partner 
drugs. Although challenging to implement, these 
alternative strategies will help to ensure long-term 
eﬃ  cacy of antimalarials to reach the elimination goal.
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